Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Saved in:
| Title: | Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia. |
|---|---|
| Authors: | Gil-Rojas Y; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia. Electronic address: yaneth@neuroeconomix.com., Lasalvia P; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia., Hernández F; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia., Castañeda-Cardona C; Department of Economic Studies, Neuroeconomix, Bogotá, Colombia., Castrillón-Correa J; Novartis de Colombia S.A., Bogotá, Colombia., Herrera D; Novartis de Colombia S.A., Bogotá, Colombia., Rosselli D; Faculty of Medicine, Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Hospital San Ignacio, Bogotá, Colombia. |
| Source: | Value in health regional issues [Value Health Reg Issues] 2021 Dec; Vol. 26, pp. 182-190. Date of Electronic Publication: 2021 Oct 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101592642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-1102 (Electronic) Linking ISSN: 22121099 NLM ISO Abbreviation: Value Health Reg Issues Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2212-1102 |
|---|---|
| DOI: | 10.1016/j.vhri.2021.04.008 |
